Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy.
Although modern social structure and medical advances have led to the increasing number of women childbearing in older age, cancer remains a rare diagnosis during pregnancy. There is little given information throughout the literature concerning gestation associated with the coexistence of gastrointestinal stromal tumor (GIST). In this review, we present 12 reported cases of GIST during pregnancy and we discuss the maternal and fetal outcome, as well as the therapeutic plan that was followed in each situation. From the collected data, 8 out of 12 cases had an uneventful outcome of their fetus. In 11 out of 12 cases surgical excision of the tumor was the treatment of choice, while seven women were treated with imatinib. Two of them were already on imatinib therapy during conception due to preexisting GIST diagnosis. Surgery remains the gold standard for the treatment of local or resectable GIST, while published data concerning the use of imatinib during pregnancy indicate that teratogenicity or fetal loss might be induced, especially if given during the first trimester of pregnancy. GIST during gestational period is a rare tumor in which a multidisciplinary approach should be designed, taking always into consideration that it has a favorable outcome on targeted treatment.
['Zarkavelis|G|G|', 'Petrakis|D|D|', 'Pavlidis|N|N|']
D000970:Antineoplastic Agents D013505:Digestive System Surgical Procedures D005260:Female D046152:Gastrointestinal Stromal Tumors D006801:Humans D000068877:Imatinib Mesylate D011247:Pregnancy D011252:Pregnancy Complications, Neoplastic D011256:Pregnancy Outcome D016896:Treatment Outcome
Gastrointestinal stromal tumor Pregnancy Gestation GIST Imatinib